Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Medtronic
Merck
Boehringer Ingelheim
McKesson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Obinutuzumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Obinutuzumab: Patents, clinical trial progress, indications

Obinutuzumab is an investigational drug.

There have been 129 clinical trials for Obinutuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and National Cancer Institute (NCI).

There are twenty-four US patents protecting this investigational drug and nine hundred and forty international patents.

Recent Clinical Trials for Obinutuzumab
TitleSponsorPhase
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaGenentech, Inc.Phase 2
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaEmory UniversityPhase 2
Venetoclax and Obinutuzumab for Relapsed Primary CNS LymphomaUniversity Hospital FreiburgPhase 1

See all Obinutuzumab clinical trials

Clinical Trial Summary for Obinutuzumab

Top disease conditions for Obinutuzumab
Top clinical trial sponsors for Obinutuzumab

See all Obinutuzumab clinical trials

US Patents for Obinutuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Obinutuzumab   Start Trial Antibody targeting cell surface deposited complement protein C3d and use thereof The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA)   Start Trial
Obinutuzumab   Start Trial Salts and solid form of a BTK inhibitor PRINCIPIA BIOPHARMA INC. (South San Francisco, CA)   Start Trial
Obinutuzumab   Start Trial Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione Celgene Corporation (Summit, NJ)   Start Trial
Obinutuzumab   Start Trial Mesalamine for the treatment of cancer Cipla Limited (Mumbai, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Obinutuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Obinutuzumab Canada 2936346 2034-01-08   Start Trial
Obinutuzumab European Patent Office 3092252 2034-01-08   Start Trial
Obinutuzumab World Intellectual Property Organization (WIPO) 2015105973 2034-01-08   Start Trial
Obinutuzumab Australia 2015218713 2034-02-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
McKinsey
Merck
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.